产品展示更多>>
- 6-Mercaptopurine monohydrate 6112-76-1

- 6-Mercaptopurine monohydrate 6112-76-1
6-Mercaptopurine monohydrate 6112-76-1
产品描述 描述 6-Mercaptopurine anhydrous is a Nucleoside Metabolic Inhibitor. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
纯度 >98%储存/保存方法 Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.基本信息 别名 6-巯基嘌呤水合物外观 黄色结晶性粉末可溶性/溶解性 DMSO : 32 mg/mL (188.03 mM; Need ultrasonic and warming)生物活性 靶点 DNA synthesis,PRPP AmidotransferaseIn vitro(体外研究) 6-Mercaptopurine hydrate (6-MP) induces NR4A3 transcriptional activity 1.6- to 11-fold (P<0.01) in a dose-responsive manner. It is found that 6-Mercaptopurine hydrate leads to a dose-dependent increase in NR4A3 protein levels. 6-Mercaptopurine hydrate treatment increases cell surface GLUT4 in both basal cells 1.8- to 3.6-fold (P<0.01) and insulin-stimulated cells 2.9- to 4.4-fold (P<0.01) over that in controls. It is also found that 6-Mercaptopurine hydrate increases phospho-AS160 significantly in a dose-responsive manner under both basal and insulin-stimulated conditions.In vivo(体内研究) In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returnes to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h.参考文献 参考文献 1. Sahasranaman S, et al. Eur J Clin Pharmacol, 2008, 64(8), 753-767.
2. Weinshilboum RM, et al. Am J Hum Genet, 1980, 32(5), 651-662.
研究领域 研究领域 CancerCancer MetabolismDrug DiscoverySmall Molecule DrugLead Compound Discovery6-Mercaptopurine monohydrate 6112-76-1温馨提示:本产品仅作科研实验使用,不支持临床等研究
